Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase [0.03%]
一种新型聚乙二醇化欧文氏菌天冬酰胺酶的优化药代动力学和药效学特性
Tapasvi Modi,David Gervais
Tapasvi Modi
Introduction: Erwinase® (native Erwinia chrysanthemi L-Asparaginase (nErA)) is an approved second-line treatment for acute lymphoblastic leukaemia (ALL) in children and adolescents, who develop hypersensitivity or neutra...
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors [0.03%]
伊沙佐米联合厄洛替尼治疗晚期实体瘤I期临床研究
Shumei Kato,Jacob J Adashek,Vivek Subbiah et al.
Shumei Kato et al.
Preclinical studies have shown that the combined inhibition of EGFR and NF-kB pathways to target the RalB/TBK1 pathway led to synergistic antitumor activity. Based on this rationale, we conducted a Phase I dose-escalation study combining th...
Clinical Trial
Investigational new drugs. 2022 Feb;40(1):99-105. DOI:10.1007/s10637-021-01153-y 2022
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma [0.03%]
Ponatinib治疗FGF受体改变的胆管癌患者I期研究
Daniel H Ahn,Pedro Luiz Serrano Uson Junior,Peter Masci et al.
Daniel H Ahn et al.
Background Biliary tract cancers (BTC) are rare, chemo resistant and are associated with a poor prognosis. Preclinical and early clinical work had demonstrated interesting anti-tumor activity from targeting fibroblast growth factor receptor...
Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents [0.03%]
设计、合成及生物评估组蛋白去乙酰基酶和血管内皮生长因子受体双靶标抗肿瘤剂抑制剂
Xia Xue,Yingjie Zhang,Yongxiang Liao et al.
Xia Xue et al.
Herein, a novel series of dual histone deacetylase (HDAC) and vascular endothelial growth factor receptor (VEGFR) inhibitors were designed, synthesized and biologically evaluated based on previously reported pazopanib-based HDAC and VEGFR d...
Successful treatment of a case of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen [0.03%]
他莫昔芬成功治疗一例激素受体阳性转移性外阴Paget病病例报告
Kohsuke Isomoto,Koji Haratani,Satomi Watanabe et al.
Kohsuke Isomoto et al.
Extramammary Paget disease (EMPD) is a rare cutaneous adenocarcinoma that usually is of epidermal origin and shows glandular differentiation and that is treated by wide local excision depending on the disease extent. For widely metastatic d...
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors [0.03%]
伏林那非联合顺铂治疗晚期实体瘤I期临床试验
Yannis Metaxas,Carmen Kahatt,Vicente Alfaro et al.
Yannis Metaxas et al.
Background In vitro/in vivo data showed synergism of cisplatin and lurbinectedin in ovarian cancer cells and grafts. This phase I trial investigated the recommended phase II dose (RD) of cisplatin and lurbinectedin combination, with (Group ...
Clinical Trial
Investigational new drugs. 2022 Feb;40(1):91-98. DOI:10.1007/s10637-021-01142-1 2022
Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report [0.03%]
BRAF和MEK抑制剂治疗BRAF V600E突变非小细胞肺癌引起的药物性结肠炎1例报告
Francesco Gelsomino,Alessandro Di Federico,Maria Lucia Tardio et al.
Francesco Gelsomino et al.
Introduction: The combination of BRAF and MEK inhibitors has deeply changed the treatment of BRAF V600-mutant non-small cell lung cancer patients. These agents demonstrated high antitumor activity as well as safe and mana...
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma [0.03%]
一项多中心I/II期研究，评估抗代谢小分子药物RX-3117联合白蛋白结合型紫杉醇治疗胰腺导管腺癌的安全性、药代动力学、药效学和疗效
Hani Babiker,Peter J Schlegel,Lee G Hicks et al.
Hani Babiker et al.
Background RX-3117 is an oral small molecule antimetabolite, cyclopentyl pyrimidyl nucleoside that is activated by cancer cells over-expressing uridine cytidine kinase 2 (UCK2). Single agent RX-3117 demonstrated efficacy in a phase I trial ...
Clinical Trial
Investigational new drugs. 2022 Feb;40(1):81-90. DOI:10.1007/s10637-021-01164-9 2022
Reforms of regulatory pathways for approval of new antineoplastic drugs in Japan from 2004 to 2019 and accompanying changes in pivotal clinical trial designs [0.03%]
日本抗癌药物审批监管路径的改革及其关键临床试验设计的变化（2004至2019年）
Takehiro Hirai,Asuka Suzuki,Takao Yamori et al.
Takehiro Hirai et al.
Background The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) was established in 2004. Since then, various pieces of legislation, notices, and guidelines have been issued, and the regulatory approval pathways for domestic drugs ...
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK) [0.03%]
体外和临床研究确定小分子神经生长酪氨酸受体激酶（NTRK）抑制剂恩曲替尼的药物相互作用潜力
Georgina Meneses-Lorente,Stephen Fowler,Elena Guerini et al.
Georgina Meneses-Lorente et al.
Background Entrectinib is a CNS-active, potent inhibitor of tyrosine receptor kinases A/B/C, ROS1 and anaplastic lymphoma kinase approved for use in patients with solid tumors. We describe the in vitro and clinical studies investigating pot...